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We here provide functional and immunocytochemical evidence supporting the
co-localization and functional interaction between nicotinic acetylcholine receptors
(nAChRs) and N-methyl-D-aspartic acid receptors (NMDARs) in glutamatergic terminals
of the nucleus accumbens (NAc). Immunocytochemical studies showed that a significant
percentage of NAc terminals were glutamatergic and possessed GluN1 and α7-containing
nAChR. A short-term pre-exposure of synaptosomes to nicotine (30 µM) or choline (1
mM) caused a significant potentiation of the 100 µM NMDA-evoked [3H]D-aspartate
([3H]D-Asp) outflow, which was prevented by α-bungarotoxin (100 nM). The pre-exposure
to nicotine (100 µM) or choline (1 mM) also enhanced the NMDA-induced cytosolic
free calcium levels, as measured by FURA-2 fluorescence imaging in individual NAc
terminals, an effect also prevented by α-bungarotoxin. Pre-exposure to the α4-nAChR
agonists 5IA85380 (10 nM) or RJR2429 (1 µM) did not modify NMDA-evoked ([3H]D-Asp)
outflow and calcium transients. The NMDA-evoked ([3H]D-Asp) overflow was partially
antagonized by the NMDAR antagonists MK801, D-AP5, 5,7-DCKA and R(-)CPP and
unaffected by the GluN2B-NMDAR antagonists Ro256981 and ifenprodil. Notably,
pre-treatment with choline increased GluN2A biotin-tagged proteins. In conclusion, our
results show that the GluN2A-NMDA receptor function can be positively regulated in
NAc terminals in response to a brief incubation with α7 but not α4 nAChRs agonists.
This might be a general feature in different brain areas since a similar nAChR-mediated
bolstering of NMDA-induced ([3H]D-Asp) overflow was also observed in hippocampal
synaptosomes.
Keywords: nicotinic receptors, NMDA receptors, nicotine treatment, neurotransmitters release, synaptosomes,
nucleus accumbens
INTRODUCTION
Adaptive changes in the glutamatergic inputs triggering
information processing in the nucleus accumbens (NAc)
Abbreviations: ECL, enhanced chemiluminescence; NAc, nucleus accumbens;
nAChR, nicotinic acetylcholine receptors; NMDAR, N-methyl-D-aspartate
receptor; PBS, phosphate-buffered saline; BSA, bovine serum albumin; t-TBS,
Tris-buffered saline-Tween; 5IA85380, 5-iodo-A-85380; FURA-2AM, Fura-
2-acetoxymethyl ester; DHβE, dihydro-β-erythroidine; R(-) CPP, 3-((R)-2-
Carboxypiperazin-4-yl)-propyl-1-phosphonic acid; MK801, (5R,10S)-(-)-
5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cylcohepten-5,10-imine maleate;
5,7-DCKA, 5,7-Dichloro-4-hydroxyquinoline-2-carboxylic acid; D-AP5,
D-(-)-2-Amino-5-phosphonopentanoic acid; Ro256981, (αR,βS)-α -(4-
Hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol maleate;
RJR2403, (E)-N-Methyl-4-(3-pyridinyl)-3-buten-1-amine oxalate.
are increasingly recognized as key features underlying mood
dysfunction and addiction (Carlezon and Thomas, 2009; Reissner
and Kalivas, 2010). In particular N-methyl-D-aspartic acid
receptors (NMDARs) play a critical role in these adaptive changes
(Ma et al., 2009), which are modulated by the cholinergic system,
namely through nicotinic acetylcholine receptors (nAChRs;
Giocomo and Hasselmo, 2007; Timofeeva and Levin, 2011).
These two signaling systems are intertwined as heralded by the
ability of nicotine to modulate both the subunit composition
(Delibas et al., 2005; Levin et al., 2005; Wang et al., 2007) and
several functions of NMDAR (Yamazaki et al., 2006; Liechti
and Markou, 2008; Lin et al., 2010; Li et al., 2013; Ávila-Ruiz
et al., 2014; Callahan et al., 2014; Salamone et al., 2014). This
interaction between nAChR and NMDAR seems most evident
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in nerve terminals (Lin et al., 2010; Salamone et al., 2014): this
is of particular interest in view of the increasingly recognized
role of presynaptic NMDARs in the control of synaptic plastic
changes in different brain areas (Sjöström et al., 2003; Corlew
et al., 2008; Bidoret et al., 2009). Thus, we now combined
immunological, pharmacological and neurochemical approaches
applied to purified nerve terminals to study NMDAR function in
glutamatergic terminals in the NAc and we tested whether these
presynaptic NMDARs were controlled by nAChRs.
MATERIALS AND METHODS
ANIMALS AND BRAIN TISSUE PREPARATION
Adult male rats (Sprague–Dawley, 200–250 g) were housed at
constant temperature (22 ± 1◦C) and relative humidity (50%)
under a regular light–dark schedule (light 7.00 a.m.–7.00 p.m.)
with food and water freely available. The experimental procedures
were approved by the Ethical Committee of the Pharmacology
and Toxicology Section (University of Genoa) (protocol num-
ber 124/2003-A), in accordance with the Italian and European
legislation on animal experimentation (2010/63/EU). All efforts
were made to minimize animal suffering and to use the minimal
number of animals required to produce reliable results.
PREPARATION OF SYNAPTOSOMES
Synaptosomes were prepared essentially as previously described
(Grilli et al., 2008, 2009). Rats were killed by decapitation, their
brains were rapidly removed at 0–4◦C and dissected to collect
the NAc (sections between Bregma 0.7–2.2 mm), according to
the atlas of Paxinos and Watson (1986), or the hippocampus.
The tissue was homogenized in 40 volumes of 0.32 M sucrose,
buffered to pH 7.4 with phosphate (final concentration 0.01
M). The homogenate was centrifuged at 1000 g for 5 min, to
remove nuclei and cellular debris, and crude synaptosomes were
isolated from the supernatant by centrifugation at 12,000 g for
20 min. The synaptosomal pellet was then resuspended in Krebs
medium with the following composition (mM): NaCl 128, KCl
2.4, CaCl2 3.2, KH2PO4 1.2, MgSO4 1.2, HEPES 25, glucose
10, pH 7.2–7.4. The purification of nerve terminals for calcium
imaging and immunocytochemical assays was carried out using a
sucrose/Percoll fractionation, as previously described (Rodrigues
et al., 2005).
NEUROTRANSMITTER RELEASE
The release of glutamate was gauged using the non-metabolizable
tracer [3H]D-aspartate ([3H]D-Asp), which was loaded by incu-
bation of the synaptosomes for 20 min at 37◦C with 0.08 µM
[3H]D-Asp. Identical samples of the synaptosomal suspension
were then layered over microporous filters at the bottom of
parallel superfusion chambers thermostated at 37◦C and the
synaptosomes were superfused with a flow rate of 0.5 mL/min
with Krebs medium. After 36 min (t = 36 min), four consecutive
3-min fractions of the eluent were collected. Synaptosomes were
then exposed to NMDAR agonists (100 µM NMDA and 10 µM
glycine) or to depolarizing agent (4-aminopyridine, 4AP, 10 µM)
from t = 39 min onwards, while antagonists were present from 8
min before addition of the agonists onwards. Exposure to nAChR
agonists was done at t = 29 min for 10 min in absence or in
presence of nAChR antagonists. The superfusate samples and
the synaptosomes were then counted for radioactivity. Agonist
effects were expressed as percent of the induced outflow over basal
outflow, upon subtraction of the radioactivity released in the four
fractions collected under basal condition (no drug added) from
that released in presence of the stimulus.
CALCIUM IMAGING
Purified nerve terminals (500 µg of protein) were resuspended
in 1 mL of HEPES-buffered medium (HBM with 122 mM NaCl,
3.1 mM KCl, 0.4 mM KH2PO4, 5 mM NaHCO3, 1.2 mM MgSO4,
10 mM HEPES, 10 mM glucose, pH 7.4). They were loaded
with FURA-2 through incubation with HBM supplemented with
5 µM FURA-2-AM, 0.02% pluronic acid F-127, 0.1% bovine
serum albumin (BSA, fatty-acid free) and 1.33 mM CaCl2 for
1 h at 25◦C and then allowed to attach onto poly-D-lysine-coated
coverslips. The terminals were washed with HBM containing
1.33 mM CaCl2 and mounted in a small superfusion chamber
(RC-20; Warner Instruments, Harvard, UK) on the stage of an
inverted fluorescence microscope (Axiovert 200; Carl Zeiss, Jena,
Germany).
Nerve terminals were alternately excited with UV light cen-
tered at 340 and 380 nm using an optical splitter (Lambda DG4;
Sutter Instruments, Novato, CA, USA), with an exposure time
of 2360 ms, and the emitted fluorescence images were captured
through a 40× oil objective and a 510 nm band-pass filter (Carl
Zeiss) connected to a digital camera (Cool SNAP; Roper Scientific,
Trenton, NJ, USA). Results were expressed by plotting the time
course of the ratio, R, of the average fluorescence light intensity
emitted by a small elliptical region inside each terminal upon
alternated excitation at 340 and 380 nm (R = F340/F380).
Increases in R correspond to increases of the levels of cytosolic
free calcium, [Ca2+] (Lev-Ram et al., 1992; Castro et al., 1995).
The basal ratio was measured during 60 s (i.e., 12 cycles) before
stimulating the nerve terminals by superfusion with NMDA (100
µM) + glycine (10µM) for 60 s. To measure the effects of the pre-
treatment with different agonists and antagonists, nicotine (100
µM), 5IA85380 (10 nM), choline (1 mM) and α-bungarotoxin
(10 nM) were added 1 min before the stimulus. A 30 s pulse of KCl
(25 mM) was applied at the end of each experiment to confirm
the viability of the studied nerve terminals. Changes in Calcium
response were measured as ∆R, subtracting the baseline (before
the drug stimulation) to the peak (after the drug stimulation). All
tested compounds were prepared in HBM medium lacking Mg2+
ions to disclose the NMDA receptor-mediated effect, and they
were added to the superfused nerve terminals, through a pressur-
ized fast-exchange solution delivery system (AutoMate Scientific,
Berkeley, CA, USA), with constant gassing of all superfusion
solution with 95% O2/5% CO2.
IMMUNOCYTOCHEMICAL ASSAYS
Nerve terminals (500 µg of protein) were resuspended in 1 mL
of phosphate-buffered saline (PBS, composed of 137 mM NaCl,
2.6 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4)
and allowed to attach onto poly-D-lysine-coated coverslips. The
follow-up immuno-characterization of the nerve terminals used
in FURA-2 fluorescence imaging experiments required the use
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of grid-etched glass coverslips. The platted nerve terminals were
fixed with 4% (w/v) paraformaldehyde for 15 min, washed twice
with PBS, permeabilized in PBS with 0.2% Triton X-100 for
10 min, and then blocked for 1 h in PBS with 3% BSA and
5% normal horse serum and washed twice with PBS. Triplicate
coverslips from each sample were incubated at 25◦C for 1 h
and the primary antibodies were diluted in PBS with 3% BSA
and 5% normal horse serum: mouse anti-GluN1 (1:500), guinea
pig anti-vGLUT (1:1000), rabbit anti-α7 nAChR (1:500), rabbit
anti-α4 nAChR (1:500). After three washes with PBS containing
3% BSA and 3% normal horse serum, the nerve terminals were
incubated for 1 h at room temperature with AlexaFluor-594 (red)-
labeled goat anti-rat IgG secondary antibodies (1:200) together
with Alexa Fluor-488 (green)-labeled donkey anti-rabbit and with
Alexa Fluor-350 (blue)-labeled donkey anti-mouse IgG secondary
antibodies (1:200). We confirmed that the secondary antibodies
only yielded a signal in the presence of the adequate primary
antibodies and that the individual signals obtained in double-
labeled fields were not enhanced over the signals obtained under
single-labeling conditions. After washing and mounting onto
slides with Prolong Antifade, the preparations were visualized in
a Zeiss Axiovert 200 inverted fluorescence microscope equipped
with a cooled CCD camera and analyzed with AxioVision software
(version 4.6). Each coverslip was analyzed by counting three
different fields containing a minimum of 500 elements each.
BIOTINYLATION AND IMMUNOBLOTTING
Synaptosomes from the NAc of two rats were re-suspended in
HBM at 4◦C. The cell surface density of GluN2A was evaluated by
performing surface biotinylation followed by immunoblots anal-
ysis, as previously described (Ciruela et al., 2006), with minimal
modications. The synaptosomes were divided into two aliquots
(500 µg protein each) and both were incubated for 10 min at
37◦C under mild shaking; one aliquot was then treated for 10
min with 1 mM choline (T) while the other was kept as control
(C). Choline exposure was terminated by dilution in cold washing
buffer composed of 150 mM NaCl, 1 mM EDTA, 0.2% BSA,
20 mM Tris, pH 8.6. After washing twice in ice-cold washing
buffer, the synaptosomes were labeled with 2 mg/ml of sulfo-
NHS-SS-biotin in PBS with 1.5 mM MgCl2 and 0.2 mM CaCl2,
pH 7.4 (PBS/Ca-Mg) for 1 h at 4◦C. The biotinylation reaction
was stopped by incubating with 1 M NH4Cl for 15 min at 4◦C,
followed by two washes with ice cold 100 mM NH4Cl in PBS/Ca-
Mg, to quench biotin. Subsequently, biotinylated synaptosomes
were lysed in RIPA buffer (500 µL) composed of 150 mM NaCl,
1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% sodium deoxy-
cholate, 1 mM orthovanadate, protease inhibitor cocktail and
10 mM Tris, pH 7.4. The lysate was centrifuged at 20,000 × g
for 10 min at 4◦C, and samples (100 µg) were incubated with
streptavidin magnetic beads (40 µL) for 1 h at room tempera-
ture under shaking. Biotinylated proteins, linked to streptavidin
magnetic beads, were then added to pulled-down by exposure
of the mixture to a magnetic field. After extensive washes, 1 ×
SDS-PAGE buffer was added and samples were boiled for 5
min at 95◦C. Proteins were then loaded and electrophoretically
separated on a 10% sodium dodecyl sulfate-PAGE gel and then
transferred to PVDF membranes and probed for the proteins
of interest by incubation with rabbit anti-GluN2A (1:2,000) or
mouse anti-β -actin (1:10,000) primary antibodies for 1 h at
room temperature with Tween 20-containing Tris-buffered saline
(t-TBS), composed of 150 mM NaCl, 0.1% Tween 20, 5% non-fat
dried milk and 20 mM Tris, pH 7.4. After washing, membranes
were incubated for 1 h at room temperature with the appropri-
ate horseradish peroxidase-linked secondary antibody (1:20,000),
and immunoblots were visualized with an ECL (enhanced chemi-
luminescence) Plus Western blotting detection system. GluN2A
subunit density was determined in the total synaptosomal lysate
(Syn) and in the streptavidin-pulled-down fraction of control
and choline-pretreated biotinylated synaptosomes (Ctr and Ch,
respectively).
DATA ANALYSIS
Statistical comparison of the results was carried out using a
Student’s t-test for independent means (for single pairs compar-
ison); multiple comparisons were performed with one- or two-
way ANOVA followed by Tukey-Kramer post hoc test. Values are
expressed as means ± SEM and are considered significant for
p< 0.05.
MATERIALS
[2,3-3H]D-aspartate (specific activity 11.3 Ci/mmol) was from
Perkin Elmer (Boston, MA, USA); nicotine hydrogen tartrate salt,
4-aminopyridine (4-AP), N-methyl-D-aspartate (NMDA), fatty-
acid free BSA, anti-β-actin monoclonal mouse IgG1, horseradish
peroxidase-conjugated anti-mouse and anti-rabbit secondary
antibodies and the protease inhibitor cocktail were from Sigma-
Aldrich (St. Louis, MO, USA); 5-iodo-A-85380, ifenprodil,
Ro256981, 5,7-dicholoro-kynuremic acid (DCKA), D-AP5, MK-
801, (R)-CPP and RJR-2403 oxalate were from Tocris (Bris-
tol, UK); FURA-2 AM, pluronic acid F-127 were performed
by Molecular Probes, Leiden, Netherlands. β-actin monoclonal
mouse IgG1, horseradish peroxidase-conjugated anti-mouse
and anti-rabbit secondary antibodies protease inhibitor cock-
tail were obtained from Sigma Chemical Co. (St. Louis, MO,
USA). Sulfo-NHS-SS-biotin and Streptavidin 14. Magnetic Beads
were purchased from Pierce Thermo Scientific (Rockford, IL,
USA), Western blotting detection system was purchased from
GeHealthcare (Italy). Guinea pig anti-vGLUT, mouse anti-GluN1,
AlexaFluor-594 (red)-labeled goat guinea pig IgG, Alexa Fluor-
488 (green)-labeled donkey anti-rabbit, Alexa Fluor-350 (blue)-
labeled donkey anti-mouse, secondary antibodies were from
Invitrogen. Rabbit anti-α4 nAChR (1:500), rabbit anti-α7 nAChR
and anti-rabbit polyclonal GluN1 antibody was from Chemicon
International (Millipore, Billerica, MA, USA).
RESULTS
CO-LOCALIZATION AND FUNCTIONAL INTERACTION OF nAChR AND
NMDAR IN GLUTAMATERGIC TERMINALS OF THE RAT NUCLEUS
ACCUMBENS
Figure 1 shows that NMDA (100 µM, plus 1 µM glycine)
triggered the release of [3H]D-Asp from pre-labeled NAc synap-
tosomes. A 10 min pre-exposure of the synaptosomes to
nicotine (100 µM) or choline (1 mM) significantly poten-
tiated the NMDA-induced [3H]D-Asp outflow (+58%, and
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FIGURE 1 | Impact of the pre-treatment during 10 min with different
nAChR agonists on the ability of NMDAR agonists (100 µM NMDA and
10 µM glycine) and of 4-AP to trigger [3H]D-Asp from rat NAc nerve
terminals. Data are means ± SEM of at least five experiments run in
triplicate. *p < 0.05 vs. control; #p < 0.05 vs. pretreatment with choline.
+56%, respectively). This potentiation was abolished in synap-
tosomes pretreated with the selective α7 nAChR antagonist
α-bungarotoxin (100 nM; Figure 1). In contrast, the pre-
exposure of the synaptosomes to the selective α4-nAChR
agonist 5IA85380 (10 nM) or RJR2403 (1 µM) did not
modify the NMDA-induced [3H]D-Asp outflow. It should be
noted that the pre-treatment of NAc synaptosomes with nico-
tine failed to modify the 4-AP-induced [3H]D-Asp outflow
(Figure 1).
The amplitude of the NMDA (100 µM, plus 10 µM glycine)-
induced increase in cytosolic free calcium in individual
NAc terminals (Figures 2A,B) was also potentiated by pre-
exposure to nicotine (100 µM; Figures 2A,B) or choline (1 mM;
Figures 2C,D), an effect that was blunted by α-bungarotoxin
(10 nM; Figures 2E,F). These observations provide further
evidence that the activation of α7-containing nAChR bolsters
NMDAR-mediated functions in NAc synaptosomes.
We next carried out an immunocytochemical characterization
of NAc nerve endings to gauge the extent of the co-localization
between α7 nAChR and NMDAR in glutamatergic nerve
terminals. As shown in Figure 3, we identified individual nerve
terminals (e.g., terminal 1) that were glutamatergic (vGluT1-
positive) and endowed with both GluN1 and α7 subunits
(Figures 3B,C), where the pre-treatment with choline (1 mM)
potentiated the NMDA (100 µM)-induced calcium transient
(Figure 3A). In fact, this analysis revealed that more than 40%
of glutamatergic nerve terminals (vGluT1-positive) possessed
GluN1 and α7 subunits (Figure 3D), thus confirming that the co-
localization of NMDAR and α7 nAChR on the same glutamatergic
terminal is a generalized feature in the NAc. The analysis of
individual NAc terminals further revealed non-glutamatergic
(vGluT1-negative) NAc terminals (e.g., terminal 2) containing
both GluN1 and α7 subunits (Figures 3B,C), where choline (1
mM) failed to modify the NMDA (100 µM)-induced calcium
transient (Figure 3A). We also found terminals that responded
FIGURE 2 | (A, C, E) Time course of FURA-2 fluorescence emission in
individual nerve terminals from the rat NAc, which were challenged twice
with NMDAR agonists (100 µM NMDA and 10 µM glycine), before and 60 s
after pre-treatment with either 100 µM nicotine (A), 1 mM choline (C) or 1
mM choline together with 10 nM α-bungarotoxin (E). (B, D, F) Comparison
of the average modification of calcium transients caused by NMDA agonists
before (open bars) and 60 s after (filled bars) the exposure to 100 µM
nicotine (B), 1 mM choline (D) or 1 mM choline together with 10 nM
α-bungarotoxin (F). Drugs were applied for 60 s, at the end of the wash out
of the previous application and the arrows identify the peaks. Values are
mean ± SEM of at least four experiments *p < 0.05 and ***p < 0.001,
using a paired Student’s t test.
only to the α7 nAChR agonist (e.g., terminal 3 in Figure 3A) or
to NMDA (e.g., terminal 4 in Figure 3A).
We also identified individual glutamatergic nerve terminals
(vGluT1-positive) containing both GluN1 and α4 subunits (ter-
minal 2; Figures 4B,C), where the pre-treatment with 5IA85380
(10 nM) did not modify the NMDA (100 µM)-induced cal-
cium transient (Figure 4A). Interestingly, we found other ter-
minals (e.g., terminal 1) also containing both GluN1 and α4
subunits, where the pre-treatment with 5IA85380 (10 nM) actu-
ally reduced the NMDA (100 µM)-induced calcium transients
(Figure 4A), a phenomenon previously observed in dopamin-
ergic NAc terminals (Salamone et al., 2014). Additionally, we
also observed nerve terminals responding only to NMDA (e.g.,
terminal 3) or to an α4 nAChR agonist (e.g., terminal 4 in
Figure 4A). The average co-localization betweenGluN1 and α4
subunits (Figure 4D) showed that only 3–4% of the NAc
glutamatergic nerve endings were endowed with both subunits, in
contrast to the frequent co-localization of GluN1 and α7 subunits
(Figure 3D).
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FIGURE 3 | Different impact of choline (1 mM) pre-treatment on the
ability of NMDAR agonists to trigger calcium transients in different
individual terminals from the rat NAc. (A) Time course of FURA-2
fluorescence emission in different individual nerve terminals (terminal
1–terminal 4), which were challenged twice with NMDAR agonists (100
µM NMDA and 10 µM glycine), before and 60 s after pre-treatment
with 1 mM choline. Drugs were applied for 60 s, at the end of the
wash out of the previous application and the arrows identify the
peaks. (B) Fluorescence image of a field of FURA- 2-labelled
synaptosomes including terminals 1–4. (C) Immunocytochemical
co-localization of α7-nAChR, vGLUT and GluN1 in terminal 1. (D)
Average co-localization of α7-nAChR, vGLUT and GluN1 in nerve
terminals from the rat NAc. Values are mean ± S.E.M of at least
four experiments.
PHARMACOLOGICAL CHARACTERIZATION OF NMDAR PRESENT IN
NAc GLUTAMATERGIC TERMINALS
The pharmacological characterization of the NMDAR involved
in the NMDA (100 µM)-evoked [3H]D-Asp outflow from
NAc synaptosomes is presented in Figure 5. The NMDA
(100 µM)-evoked [3H-]D-Asp outflow was antagonized
by MK801 (10 µM) and by D-AP5 (1 µM), as well as
by the selective GluN1 antagonist 5,7-DCKA (1 µM).
Furthermore, the GluN2A-preferring antagonist (R)-CPP
(1 µM) also attenuated the NMDA (100 µM)-evoked
[3H]D-Asp outflow (−48%), while the GluN2B-selective
antagonists Ro256981 (1 µM) and ifenprodil (1 µM) were
ineffective.
nAChR ACTIVATION DRIVES GluN2A TRAFFICKING TO THE PLASMA
MEMBRANE
We next tested whether nicotine pre-treatment selectively
impacts this NR2A-mediated component of the NMDA-evoked
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FIGURE 4 | Different impact of 5IA85380 (10 nM) pre-treatment on
the ability of NMDAR agonists to trigger calcium transients in
different individual terminals from the rat NAc. (A) Time course of
FURA-2 fluorescence emission in different individual nerve terminals
(terminal 1–terminal 4), which were challenged twice with NMDAR
agonists (100 µM NMDA and 10 µM glycine), before and 60 s after
pre-treatment with 5IA85380 (10 nM). Drugs were applied for 60 s, at
the end of the wash out of the previous application and the arrows
identify the peaks. (B) Fluorescence image of a field of
FURA-2-labelled synaptosomes including terminals 1–4. (C)
Immunocytochemical co-localization of α4-nAChR, vGLUT and GluN1 in
terminal 1. (D) Average co-localization of α4-nAChR, vGLUT and GluN1
in nerve terminals from the rat NAc. Values are mean ± S.E.M of at
least four experiments.
[3H]D-Asp outflow. As shown in Figure 6A, after (Choline 1
mM) pre-treatment, the inhibitory effect of the NR2A-preferring
antagonist (R)-CPP (1 µM) was significantly increased (−78%)
compared to the effects on control (non-pre-treated) synapto-
somes (−48%; Figure 5). By contrast, nicotine pre-treatment
did not enhance the inhibition caused by the NR2B-selective
antagonist Ro256981 (1 µM), which was still non-significant
(Figure 6A).
Since we have previously shown that nAChR can control
the responses of presynaptic ionotropic glutamate receptors
through the regulation of their trafficking in and out of the
plasma membrane (Grilli et al., 2012; Salamone et al., 2014),
we posited that the nicotine-induced increase of the NMDA
response in NAc glutamatergic terminals would also rely on
a control of the trafficking of GluN2A-containing NMDAR.
Indeed, the quantification of the density of biotin-tagged
Frontiers in Cellular Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 332 | 6
Zappettini et al. Nicotine-induced NMDA receptor trafficking
FIGURE 5 | Effect of different NMDAR antagonists on the evoked
[3H]D-Asp release from rat NAc synaptosomes triggered by 100 µM
NMDA and 1 µM glycine and lack of effect of GluN2B-NMDAR
antagonists (Ro256981 and ifenprodil). Data are mean ± SEM of at least
five experiments run in triplicate. *p < 0.05, **p < 0.01, ***p < 0.001 vs. 100
µM NMDA using a one-way ANOVA followed by Tukey-Kramer post hoc test.
GluN2A subunit proteins in NAc synaptosomes before and
after choline pre-treatment (Figures 6B,C) showed that choline
(1 mM) pre-treatment for 10 min increased (+15%, Figure 6C)
the density of GluN2A at the plasma membrane (Figure 6B, lane
Ch) respect to control (Figure 6B, lane Ctr).
CHOLINE POTENTIATES THE NMDA-INDUCED D-Asp RELEASE FROM
HIPPOCAMPAL NERVE TERMINALS
N-methyl-D-aspartic acid (100 µM, plus 10 µM glycine) caused
a marked outflow of [3H]D-Asp from pre-labeled hippocampal
synaptosomes (Figure 7), which was quantitatively higher than
that observed in NAc synaptosomes (cf. Figures 1, 7). The pre-
exposure of hippocampal synaptosomes to choline (1 mM) for
10 min significantly potentiated the NMDA-induced [3H]D-Asp
outflow while the pre-incubation with nicotine (100 µM) was
ineffective. As observed in NAc synaptosomes, the pre-exposure
of hippocampal synaptosomes to the α4β2 nAChR agonists
5IA85380 (10 nM) or cytisine (100 µM) for 10 min did not
modify the NMDA-induced [3H]D-Asp outflow.
DISCUSSION
The present study shows that the activation of nAChR enhances
the ability of NMDAR to trigger neurotransmitter release from
glutamatergic terminals of the NAc. Our combined pharmacolog-
ical and immunocytochemical characterization at the individual
nerve terminal level revealed that this involved the ability of
α 7-containing nAChR to selectively bolster GluN2A-containing
NMDA receptor function. Further biochemical studies showed
that nAChR activation enhanced the plasma membrane levels of
FIGURE 6 | Nicotinic acetylcholine receptors activation selectively
bolsters GluN2A-dependent [3H]D-Asp release (A) and GluN2A
membrane insertion (B, C) in NAc terminals. (A) The selective
GluN2A-NMDAR antagonist R(-)CPP, but not the GluN2B-NMDAR
antagonist Ro256981, attenuated the potentiating effect resulting
from the pre-treatment for 10 min with (1 mM Choline) of the
evoked [3H]D-Asp release from rat NAc synaptosomes triggered by
100 µM NMDA and 10 µM glycine. Values are mean ± SEM of six
experiments run in triplicate. **p < 0.01 vs. control using a one-way
ANOVA followed by Tukey-Kramer post hoc test. (B) Representative
Western blot of GluN2A subunit surface density in NAc terminals.
The Western blots compares total synaptosomal membranes before
adding biotin (Syn Tot), synaptosomal membranes that are not
treated with biotin and are subject to a streptavidin pull-down (B),
synaptosomal membranes incubated with biotin and subject to a
streptavidin pull-down (Ctr) and membranes from synaptosomes that
were pre-treated for 1 mM choline before incubation with biotin and
pull-down with streptavidin (Ch). The blots are representative of four
different experiments carried out with synaptosomal preparations
from different rats. (C) Comparison of the average density of
biotin-labelled GluN2A proteins in NAc synaptosomal membranes
without (open bars) and after (filled bars) a 10 min exposure to 100
µM nicotine. Values are mean ± SEM of four experiments.
*p < 0.05 using a paired Student’s t test.
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FIGURE 7 | Impact of the pre-treatment with different nAChR agonists
on the ability of NMDA to trigger [3H]D-Asp outflow from nerve
terminals of the rat hippocampus. Each nAChR agonist was added 10 min
before challenging with NMDA. Values are mean ± SEM of five
experiments run in triplicate. * p < 0.05 vs. control.
GluN2A subunits in NAc terminals, allowing to argue that the
nAChR-mediated control of GluN2A trafficking into the plasma
membrane underlies the potentiation of presynaptic NMDAR-
mediated actions by nAChR activation in NAc glutamatergic
terminals.
Although ionotropic receptors are traditionally recognized as
supporting fast synaptic transmission by acting as postsynaptic
sensors of released neurotransmitters, evidence accumulated over
the last decades also supports a parallel fine-tuning neuromodu-
lation role for ionotropic receptors as controllers of the release of
different neurotransmitters (MacDermott et al., 1999; Dorostkar
and Boehm, 2008), with critical impact on adaptive changes of
synaptic efficiency (Sjöström et al., 2003; Corlew et al., 2008;
Bidoret et al., 2009). Accordingly, it has been shown that differ-
ent nAChR and NMDAR subtypes are present in glutamatergic
nerve terminals in different brain areas, where they efficiently
modulate the release of glutamate (McGehee et al., 1995; Marchi
et al., 2002; Bardoni et al., 2004; Dickinson et al., 2008; Musante
et al., 2011; Gomez-Varela and Berg, 2013). The present study
provides an additional layer of complexity in the presynaptic
signaling by ionotropic receptors, dwelling on the interaction
between presynaptic ionotropic receptors. In fact, building on the
observation that different ionotropic receptors are co-localized
in nerve terminals, we explored the nature of their interac-
tions to grasp the fine-tuning of neurotransmitter release. Thus,
our immunocytochemical findings showed that both α7 and α4
nAChR were co-localized with GluN1 subunits of NMDAR in
NAc nerve terminals, namely in glutamatergic nerve endings.
This led to the key observation that the two modulation systems
are actually engaged in a cross-talk, since the pre-treatment of
NAc synaptosomes with nicotine caused a significant increase of
the NMDA-evoked intra-terminal cytosolic free calcium transient
and [3H]D-Asp outflow.
It has been previously described that glutamate exocyto-
sis is controlled by α7-nAChR and by α4β2-nAChR subtypes
(Dickinson et al., 2008; Zappettini et al., 2010). However, our
pharmacological characterization showed a primary involvement
of α7-nAChR controlling presynaptic NMDA responses, based
on the effects of the α7-nAChR-selective agonist choline and
α7-nAChR-selective antagonist α-bungarotoxin. This is further
confirmed by the lack of effect of 5IA85380, indicating the inabil-
ity α4β2-nAChR to modify the functional response of presy-
naptic NMDAR. This contention is further strengthened by our
observation that nicotine or choline triggered an increase of
the NMDA-induced intra-terminal calcium transients selectively
in glutamatergic nerve endings (see Figure 3), which were also
endowed with α7-nAChR. Notably, the impact of nAChR acti-
vation was qualitatively similar and displayed a similar phar-
macology when measuring the NMDA-induced intra-terminal
calcium transients or the release of [3H]D-Asp. This strongly
suggests that the increased NMDA-evoked outflow of glutamate
probably results from the modulation of the calcium transient.
Furthermore, it should be noted that α4-nAChR are also present
in glutamatergic terminals (see Figure 4) and can trigger calcium
entry into nerve terminals (Dickinson et al., 2007; Zappettini
et al., 2010). However, α7-nAChR triggers a direct calcium entry,
whereas the α4-nAChR-mediated increase of intra-terminal free
calcium levels involves a depolarization of the terminal and
the subsequent activation of voltage-sensitive calcium channels
(Dickinson et al., 2007). This prompts the hypothesis that the
different mechanisms of nAChR-induced raise of intra-terminal
free calcium may be linked to their different ability to control
presynaptic NMDAR function, a question that remains to be
solved.
The pharmacological characterization of the nAChR-mediated
control of presynaptic NMDAR responses also allowed establish-
ing the selective involvement of GluN2A-containing NMDAR,
in spite of the known presence of both GluN2A and GluN2B
subunits in NMDA autoreceptors located in hippocampal glu-
tamatergic nerve endings (Luccini et al., 2007). In fact, the
NMDA-induced outflow of [3H]D-Asp was selectively attenuated
by selective antagonists of GluN2A-containing NMDAR, whereas
selective GluN2B antagonists were devoid of effects. Additionally,
the pre-activation of nAChR selectively bolstered the amplitude
of the inhibitory effect of GluN2A antagonists, rather than that
of GluN2B antagonists, further indicating the selective nAChR
modulation of presynaptic GluN2A-containing NMDAR. This
was further re-enforced by the biochemical identification of an
increased density of GluN2A subunits in the plasma membrane of
NAc terminals after pre-activation of nAChR. This poses the con-
trol of the trafficking of NMDAR subunits as the likely mechanism
operated by nAChR to bolster the effects of presynaptic NMDAR,
whereas a possible impact on the exocytotic machinery is made
unlikely by the lack of effect of α7-nAChR activation on the 4AP-
evoked [3H]D-Asp outflow. Although the intracellular pathway
operated by nAChR to control GluN2A trafficking remains to be
defined, this might involve a nAChR-mediated control of kinase
activity, since NMDAR trafficking is regulated by phosphoryla-
tion (Lan et al., 2001; Chen and Roche, 2007; Lau and Zukin,
2007).
We have previously reported that nAChR also controlled
NMDAR-mediated responses in NAc dopaminergic terminals,
but we found that nAChR activation depressed presynaptic
NMDAR-mediated responses (Salamone et al., 2014), in contrast
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to the potentiation observed in NAc glutamatergic terminals
and described above. Remarkable, in NAc dopaminergic nerve
terminals, we observed that it was the activation of α4β2-nAChR
that depressed GluN2B containing NMDAR (Salamone et al.,
2014), instead of α7-nAChR potentiating GluN2A containing
NMDAR in NAc glutamatergic terminals. Taken together, these
findings indicate a striking difference between the interplay of
nAChR and NMDAR in different nerve terminals, which seems
to depend on the types of nAChR and of NMDAR playing
the prime role in each different type of nerve terminal within
the NAc. This prompted us to test if there were also differ-
ences between brain areas and we found that nAChR activa-
tion also triggered a potentiation of NMDAR-induced release of
[3H]D-Asp from hippocampal nerve terminals, as occurred in
the NAc glutamatergic terminals. It still remains to understand
the signaling mechanisms responsible for the different setup of
nAChRs and NMDARs in different types of nerve terminals in the
brain.
There is increasing recognition of the importance of presy-
naptic NMDAR on the control of synaptic plasticity (Sjöström
et al., 2003; Corlew et al., 2008; Bidoret et al., 2009), together
with the role that adaptive changes in the efficiency of glu-
tamatergic synapses may have in the addictive behavior (Ma
et al., 2009; Kalivas and Volkow, 2011; Grueter et al., 2012).
We characterized the ability of nAChRs to bolster presynaptic
NMDAR-mediated responses in NAc glutamatergic terminals.
This nAChRs-mediated control of NMDAR function in gluta-
matergic terminals of the NAc could help to understand the
parallel effects of cholinergic and glutamatergic systems on higher
brain functions involving information processing in NAc circuits
such as mood, memory or addiction (Carlezon and Thomas,
2009; Reissner and Kalivas, 2010).
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